Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Pennsylvania Jury Reportedly Finds Johnson & Johnson Baby Power Didn't Cause Disease, Bloomberg Says

09/24/2021 | 01:30pm EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
10/22Walgreens Starts Offering Moderna, Johnson & Johnson COVID-19 Booster Shots
MT
10/22CDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses
AQ
10/22MODERNA : CDC Endorses Booster Doses of Moderna, J&N COVID-19 Vaccines
MT
10/21JOHNSON & JOHNSON : U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson C..
PR
10/21JOHNSON & JOHNSON : J&J Offered to Pay $4 Billion to Resolve Talc Cancer Claims Months Bef..
MT
10/21JOHNSON & JOHNSON : Maintains Quarterly Dividend of $1.06 a Share, Payable on Dec. 7 to Sh..
MT
10/21JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2021
PR
10/21Johnson & Johnson Declares Cash Dividend for the Fourth Quarter of 2021, Payable on Dec..
CI
10/21COVID VACCINE : CDC expands booster rollout, OKs mixing shots
AQ
10/21JOHNSON & JOHNSON : UBS Adjusts Price Target on Johnson & Johnson to $175 From $183 After ..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 281 M - -
Net income 2021 22 790 M - -
Net cash 2021 302 M - -
P/E ratio 2021 19,8x
Yield 2021 2,55%
Capitalization 431 B 431 B -
EV / Sales 2021 4,57x
EV / Sales 2022 4,28x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,72 $
Average target price 185,46 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979
MERCK & CO., INC.-0.79%205 421